PT  - JOURNAL ARTICLE
AU  - Elgin Ozkan
AU  - Pınar Akkus
AU  - Begum Bahcecioglu
AU  - Mine Araz
AU  - Cigdem Soydal
AU  - Sevim Gullu
AU  - Ozlem Kucuk
TI  - Clinical outcome of low risk differentiated thyroid cancer patients treated with 30 mCi for ablation or without radioactive iodine therapy : a single center experience from Turkey<strong/>
DP  - 2019 May 01
TA  - Journal of Nuclear Medicine
PG  - 1549--1549
VI  - 60
IP  - supplement 1
4099  - http://jnm.snmjournals.org/content/60/supplement_1/1549.short
4100  - http://jnm.snmjournals.org/content/60/supplement_1/1549.full
SO  - J Nucl Med2019 May 01; 60
AB  - 1549Objectives: To retrospectively review the outcomes of patients with low risk differentiated thyroid carcinoma (DTC) treated with total thyroidectomy without radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose (30 mCi) of radioiodine following total thyroidectomy. Materials and Methods: A total of 122 DTC patients who were treated with TT either followed by 30 mCi for RRA or not, followed in single center in Turkey were included. Clinical outcomes were compared in two groups. Results: Following initial therapy, mean follow up time was 44.4 months (min:12, max:103 months). In the study group, 94.3% of all patients were ATA low-risk and 5.7% were intermediate risk. Seventy-five patients underwent RRA and 47 did not. In RRA group, two patients had extra-thyroidal extension and one had aggressive histology (tall cell variant papillary carcinoma). In the other group there were no patients with additional risk factors except for one patient with a single central lymph node metastasis. There was no significant difference in clinical outcomes in low and intermediate risk patients in both groups. Persistence of disease was found in 1 patient (1.3%) in RRA group, but not in the other group. Conclusions: In low risk patients, after TT, follow up results of patients who recieve RRA and who do not are similar with a quite favourable outcome. RRA can be beneficial in patients with additional risk factors. Personalized therapy strategies should be generated, RRA is not obligatory.